SD Bolen, E Bricker, T Samuels, HC Yeh, SS … - Diabetes care, 2009 - Am Diabetes Assoc RESULTS—Provider-patient dyads intensified oral diabetes treatment in only 128
(22%) of 574 hyperglycemic visits. As expected, worse glycemia was an important
predictor of intensification. Treatment was more likely to be intensified ... Cited by 1 - Related articles - All 4 versions
D Pitocco, D Valle, A Rossi, R Gentilella - Journal of endocrinological investigation, 2008 - ncbi.nlm.nih.gov Secondary failure is defined as a deterioration of glucose control in patients
with Type 2 diabetes on oral antidiabetic drugs (OAD), mainly due to the
progressive decline in beta-cell function and reduction in insulin ... Cited by 4 - Related articles - BL Direct - All 3 versions
SH Meeuwisse-Pasterkamp, MM van der Klauw … - Expert Review of Cardiovascular Therapy, 2008 - ingentaconnect.com Type 2 diabetes mellitus is a disease that affects a rapidly increasing number
of patients. Most patients with Type 2 diabetes will develop vascular
complications. This may be microvascular disease, such as nephropathy, ... Cited by 4 - Related articles - All 4 versions
YS Ali, MRF Linton, S Fazio - Current Opinion in Endocrinology, Diabetes and …, 2008 - journals.lww.com Recent findings: A number of clinical outcomes trials supports the use of
statins to reduce cardiovascular events in patients with type 2 diabetes
mellitus. The disappointing results of clinical trials involving ... Cited by 5 - Related articles - BL Direct - All 3 versions
- ►sherbornegibbs.com [PDF] AH Barnett - Diabetes & Vascular Disease Research, 2008 - dvr.sagepub.com Abstract C ardiometabolic risk factors are the combined vas- cular and metabolic
components of risk that may lead to a cardiovascular event. There are numerous
such factors. Underlying the concept of cardiometabolic risk is an ... Cited by 8 - Related articles - BL Direct - All 7 versions
[CITATION] Collaborative Diabetes Study Investigators. Control of diabetes and cardiovascular risk …
M Igarashi, Y Jimbu, M Kimura, A Hirata, H … - Diabetes Research and Clinical Practice, 2007 - Elsevier The aim of this study was to evaluate the anti-atherogenic efficacy of
pioglitazone, a thiazolidinedione derivative, on the change in atherogenic
outcomes by comparing responder and non-responder groups in type 2 diabetic ... Cited by 4 - Related articles - All 10 versions
SV Joy - The Diabetes Educator, 2008 - tde.sagepub.com Increasing evidence suggests that a large proportion of patients with type 2
diabetes do not meet glycemic targets. Early diagnosis, realistic goal setting,
improved patient adherence, and a better understanding of the ... Cited by 4 - Related articles - All 3 versions
[CITATION] for the Look AHEAD Research Group. Suboptimal control of glycemia, blood pressure, and …
- ►clinicalcornerstone.com [PDF] JE Gerich - Clinical Cornerstone, 2007 - Elsevier The risk for cardiovascular disease (CVD) is multifactorial and includes such
risk factors as diabetes, hypertension, smoking, and dyslipidemia. Thus,
targeting the hyperglycemia in type 2 diabetes mellitus (DM) alone will not ... Cited by 2 - Related articles - All 3 versions
